However, in clinical practice, no relationship between HER-2 overexpression and response to ZD1839 (Iressa®) was shown in a series of patients suffering from non-small-cell lung cancer (Cappuzzo et al, 2003). Here, ERBB2 is linked to non-small cell lung carcinoma.